HC Wainwright Expects Weaker Earnings for ArriVent BioPharma

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Equities research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for ArriVent BioPharma in a report released on Monday, August 17th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.04) per share for the quarter, down from their previous forecast of ($0.96). HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($3.96) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.14) EPS, Q1 2027 earnings at ($1.11) EPS, Q2 2027 earnings at ($1.16) EPS, Q3 2027 earnings at ($1.04) EPS and Q4 2027 earnings at ($0.93) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.06).

Several other research analysts have also commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Friday, July 17th. Citigroup lowered their target price on shares of ArriVent BioPharma from $43.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, August 13th. Truist Financial lifted their target price on shares of ArriVent BioPharma from $43.00 to $45.00 and gave the company a “buy” rating in a report on Friday, May 29th. BTIG Research reiterated a “buy” rating and set a $42.00 price target on shares of ArriVent BioPharma in a research note on Thursday, August 13th. Finally, Guggenheim reissued a “buy” rating and set a $45.00 price objective on shares of ArriVent BioPharma in a research report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.86.

ArriVent BioPharma Stock Up 3.4%

Shares of NASDAQ AVBP opened at $30.00 on Wednesday. The business has a 50-day moving average price of $31.75 and a 200 day moving average price of $27.95. The stock has a market cap of $1.40 billion, a PE ratio of -8.29 and a beta of 1.36. ArriVent BioPharma has a 52-week low of $17.00 and a 52-week high of $35.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AVBP. Dimensional Fund Advisors LP raised its position in ArriVent BioPharma by 758.2% in the first quarter. Dimensional Fund Advisors LP now owns 126,525 shares of the company’s stock worth $2,918,000 after acquiring an additional 111,782 shares in the last quarter. Tema ETFs LLC purchased a new stake in shares of ArriVent BioPharma during the 2nd quarter worth $1,981,000. Vivo Capital LLC purchased a new stake in shares of ArriVent BioPharma during the 1st quarter worth $20,438,000. Affinity Asset Advisors LLC grew its stake in shares of ArriVent BioPharma by 16.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 175,000 shares of the company’s stock worth $4,037,000 after purchasing an additional 25,000 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new position in shares of ArriVent BioPharma during the 1st quarter worth $1,159,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

Trending Headlines about ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright raised its price target for ArriVent BioPharma from $44 to $47 while maintaining a Buy rating. The target implies substantial potential appreciation from the referenced $30 share price, signaling confidence in the company’s long-term prospects. HC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma
• Neutral Sentiment: HC Wainwright projected continued losses through 2027, including EPS of ($1.11) in Q1 2027, ($1.16) in Q2, ($1.04) in Q3 and ($0.93) in Q4. The firm estimates a full-year 2027 loss of ($4.24), underscoring that ArriVent remains an early-stage biotechnology company reliant on future clinical and commercial progress.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS forecast to a loss of ($1.04) from ($0.96), reduced its Q4 estimate to ($1.07) from ($0.99), and cut its FY2026 forecast to a loss of ($4.14) from ($3.86). These revisions indicate higher expected near-term expenses or slower progress toward profitability and are a negative factor for the stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.